GSK delivers Q3 earnings beat, reaffirms 2026 outlook
FROM THE WIRE · SEEKINGALPHA.COM
[Glaxo Smith Kline headquarters, London] William Barton/iStock Editorial via Getty Images GSK plc (GSK [https://seekingalpha.com/symbol/GSK]) reported third-quarter core earnings per share above analyst expectations on Wednesday, as growth in specialty medicines helped offset…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishCore earnings above expectations with reaffirmed guidance is a positive signal for the drugmaker's shares.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Core EPS came in at 54.6 pence, ahead of the 50p consensus estimate.
- 02Total sales rose 4% year over year to 8.9 billion pounds.
- 03Growth in specialty medicines helped offset weakness in vaccines.
- 04The company reaffirmed its full-year 2026 outlook.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets